Echinacea
PreclinicalSmall molecule
Echinacea is one of 12 small molecule programs targeting Respiratory tract infection. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Respiratory Tract Infection
#DrugCompanyPhaseTrials
1Ketek
SanofiApproved
Tylenol
KKenvue Brands
Approved
Advil
KKenvue Brands
Approved
Tobrex
VViatris Specialty LLC
Approved
Merrem
BB. Braun Medical Inc.
Approved
Levaquin
WWim Janssens
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Biaxin
AbbViePreclinical
BEYFORTUS
SanofiPreclinical
BEZ235
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
NAC1 trial
Respiratory tract infection1 trial
Children1 trial
A Trial of Echinacea in Children
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 3·NCT00029211·600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Echinacea. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details